… ® , which uses a cell’s own editing machinery called ADAR (adenosine deaminase acting on RNA) to make specific … the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including … +1 617 599 6228 skiely@proqr.com or Hans Vitzthum LifeSci Advisors T: +1 617 430 7578 hans@lifesciadvisors.com Media …
… Axiomer®, which uses a cell’s own editing machinery called ADAR (adenosine deaminase acting on RNA) to make specific … the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including … +1 617 599 6228 skiely@proqr.com or Hans Vitzthum LifeSci Advisors T: +1 617 430 7578 hans@lifesciadvisors.com Media …
Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome
… there is currently no treatment,” said Dr. Bart Leroy, Head of the Ophthalmology Department and Professor of … and Attending Physician at The Children's Hospital of Philadelphia. “After missing the primary endpoint in the … ® , which uses a cell’s own editing machinery called ADAR (adenosine deaminase acting on RNA) to make specific …
… Annual General Meeting of Shareholders and Provides Leadership Updates Annual General Meeting of Shareholders to … ® , which uses a cell’s own editing machinery called ADAR (adenosine deaminase acting on RNA) to make specific …